[HTML][HTML] Lenalidomide after stem-cell transplantation for multiple myeloma
…, RT Maziarz, DA Gabriel, A Bashey… - … England Journal of …, 2012 - Mass Medical Soc
Background Data are lacking on whether lenalidomide maintenance therapy prolongs the
time to disease progression after autologous hematopoietic stem-cell transplantation in …
time to disease progression after autologous hematopoietic stem-cell transplantation in …
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
…, MJ Zhang, AA Bacigalupo, A Bashey… - Blood, The Journal …, 2015 - ashpublications.org
We studied adults with acute myeloid leukemia (AML) after haploidentical (n = 192) and 8/8
HLA-matched unrelated donor (n = 1982) transplantation. Haploidentical recipients received …
HLA-matched unrelated donor (n = 1982) transplantation. Haploidentical recipients received …
[HTML][HTML] Ipilimumab for patients with relapse after allogeneic transplantation
Background Loss of donor-mediated immune antitumor activity after allogeneic
hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We …
hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We …
[HTML][HTML] Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
…, EP Alyea, M Hamadani, A Bashey… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT)
is unknown. We hypothesized that lower treatment-related mortality (TRM) with …
is unknown. We hypothesized that lower treatment-related mortality (TRM) with …
[PDF][PDF] T-cell–replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in …
A Bashey, X Zhang, CA Sizemore… - Journal of Clinical …, 2013 - uclaoliveview.org
Purpose T-cell–replete grafts from haploidentical donors using post-transplantation
cyclophosphamide may represent a solution for patients who require allogeneic hematopoietic cell …
cyclophosphamide may represent a solution for patients who require allogeneic hematopoietic cell …
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
…, FR Loberiza Jr, R Bajorunaite, JO Armitage, A Bashey… - Blood, 2003 - ashpublications.org
In this article, we report on 904 patients undergoing transplantation for follicular lymphoma.
A total of 176 (19%) received allogeneic, 131 (14%) received purged autologous, and 597 (…
A total of 176 (19%) received allogeneic, 131 (14%) received purged autologous, and 597 (…
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
A Bashey, B Medina, S Corringham… - Blood, The Journal …, 2009 - ashpublications.org
Relapse of malignancy after allogeneic hematopoietic cell transplantation (allo-HCT)
remains a therapeutic challenge. Blockade of the CTLA4 molecule can effectively augment …
remains a therapeutic challenge. Blockade of the CTLA4 molecule can effectively augment …
[HTML][HTML] Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease
…, Y Li, A Licon, EP Alyea, A Bashey… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …
[HTML][HTML] Outcome of transplantation for myelofibrosis
…, KA Sobocinski, MJ Zhang, A Bashey… - Biology of Blood and …, 2010 - Elsevier
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies.
Several small series have reported long-term disease-free survival (DSF) after allogeneic …
Several small series have reported long-term disease-free survival (DSF) after allogeneic …
[HTML][HTML] Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic …
…, S Brown, HK Holland, LE Morris, A Bashey - Biology of Blood and …, 2012 - Elsevier
Haploidentical hematopoietic stem cell transplant (HSCT) provides an opportunity for nearly
all patients to benefit from HSCT. We conducted a trial of haploidentical T cell replete …
all patients to benefit from HSCT. We conducted a trial of haploidentical T cell replete …